Combos Mark Next Step in Melanoma Immunotherapy – OncLive
OncLive |
Combos Mark Next Step in Melanoma Immunotherapy
OncLive Evidence continues to build for the long-term efficacy of PD-1–targeting immunotherapies in melanoma, including fresh data indicating when patients can stop taking the drugs and still maintain a response, according to Tara C. Gangadhar, MD. The future … |
